Table 1.
Patient/tumor characteristics and surgical outcomes (DFCI and MD Anderson cohorts)
| DFCI cohort (N=55) | MD Anderson cohort (N=41) | |||
|---|---|---|---|---|
| Category | Patients: # (%) | Category | Patients: # (%) | |
| Age (median (IQR)) | 47 yrs (39–51 yrs) | 57 yrs (46–62 yrs) | ||
| HR status | ER+/PR+ | 45 (82%) | ER+/PR+ | 32 (78%) |
| ER+/PR- | 9 (16%) | ER+/PR- | 7 (17%) | |
| ER-/PR+ | 1 (2%) | ER-/PR+ | 0 | |
| Unknown | 0 | Unknown | 1 (2%) | |
| Stage at diagnosis | 1 | 2 (4%) | 1 | 1 (2%) |
| 2 | 41 (75%) | 2 | 24 (59%) | |
| 3 | 12 (22%) | 3 | 14 (34%) | |
| 4 | 0 (0%) | 4 | 1 (2%) | |
| Unknown | 0 (0%) | Unknown | 1 (2%) | |
| Grade | 1 | 3 (6%) | 1 | 2 (5%) |
| 2 | 30 (55%) | 2 | 22 (54%) | |
| 3 | 22 (40%) | 3 | 12 (29%) | |
| Unknown | 0 | Unknown | 5 (12%) | |
| Intrinsic subtype (assessed in N=38 pts from DFCI cohort) | Luminal A | 24 (63%) | ||
| Luminal B | 7 (18%) | |||
| Basal | 6 (16%) | NA | NA | |
| Normal | 1 (3%) | |||
| Not assessed | 17 | |||
| RCB* | 0 | 4 (7%) | 0 | 0 |
| 1 | 5 (9%) | 1 | 3 (7%) | |
| 2 | 22 (40%) | 2 | 22 (54%) | |
| 3 | 23 (42%) | 3 | 16 (39%) | |
| Unable to assess | 1 (2%) | Unable to assess | 0 | |
Characteristics of patients included in two separate cohorts. Stage at diagnosis indicates clinical anatomic stage according to American Joint Committee on Cancer Staging, 8th edition.
*
Patients with RCB 0 were excluded from MD Anderson cohort.
Abbreviations: DFCI, Dana-Farber Cancer Institute; IQR, interquartile range; NA, not available/not applicable; RCB, Residual Cancer Burden.